Estados Unidos · Plataformas y datos · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Publicado por TipRanks · Estados Unidos hace 10 h

Resumen detallado

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

Leer el artículo completo en TipRanks Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.tipranks.com)

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Resumen detallado

También te puede interesar

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

Resumen detallado

Compartir

También te puede interesar

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says